Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts
Common warts are estimated to affect 10 percent of the global population Currently no FDA-approved prescription treatment for common warts Phase III patient enrollment expected to start in the second half of 2023 SAN FRANCISCO, June 14, 2023 /PRNewswire/ — Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, … Read more